GoodRx is a consumer-focused digital healthcare platform that provides prescription drug pricing transparency and discounts. The company aggregates prices from a network of more than 70,000 U.S. pharmacies and issues free coupons that consumers, whether insured, uninsured, or underinsured, can use at the pharmacy counter to obtain discounted cash prices on prescription medications. Beyond prescription savings, GoodRx has expanded into adjacent healthcare services including telehealth (GoodRx Care, built on the 2019 HeyDoctor acquisition), a manufacturer-sponsored solutions business that partners with pharma brands on patient affordability programs, and a subscription product (GoodRx Gold). The company monetizes primarily through fees paid by pharmacy benefit managers (PBMs) when consumers fill prescriptions using GoodRx codes, as well as via advertising and subscription revenue. Founded in 2011 by Doug Hirsch, Trevor Bezdek, and Scott Marlette, GoodRx is headquartered in Santa Monica, California and went public on the NASDAQ Global Select Market on September 23, 2020 under the ticker GDRX.
GoodRx is publicly traded
IPO'd on September 23, 2020
This company is no longer available on our private secondary market. Shares can be traded publicly under GDRX.
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2011
Employees
700–1,100
Total Funding
$1.14B
4 rounds
Last Private Valuation
$2.8B
August 6, 2018
Total raised $1.14B across 4 rounds
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Last updated 05-21-2026
Latest Round
Type
IPO
Date
September 23, 2020
Amount
$1.14B
Valuation
$12.7B
Lead Investors
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| September 23, 2020 | IPO | $1.14B | $12.7B | Morgan Stanley, Goldman Sachs, J.P. Morgan +1 more |
| August 6, 2018 | Private Equity | Undisclosed (Silver Lake acquired approximately one-third stake) | $2.8B | Silver Lake |
| October 7, 2015 | Series B / Growth Equity | Undisclosed | — | Francisco Partners, Spectrum Equity |
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Valuation indexed to 1.0× at the selected entry round. Valuation marks are estimates and may contain errors. Hover each dot to compare.
Entry · Private Equity
$2.8B
Aug 2018
GoodRx today
$12.7B
Sep 2020 · latest mark
GoodRx multiple
4.5x
valuation uplift since first round
Y-axis is logarithmic. Hollow dots = estimated valuations. Does not represent realized investor returns.
Wendy Barnes
President and Chief Executive Officer
Chris McGinnis
Chief Financial Officer
Thomas Chan
Chief Accounting Officer
Vina Leite
Chief People Officer
Gracye Cheng
General Counsel and SVP
Trevor Bezdek
Co-Founder and Co-Chair of the Board
Doug Hirsch
Co-Founder and Chief Mission Officer
Competitor list is illustrative and may be incomplete, stale, or erroneous.
SingleCare
Boston-based prescription savings card founded 2015, free to U.S. residents over 13, accepted at 35,000+ pharmacies; closest direct competitor to GoodRx's coupon model.
Optum Perks
UnitedHealth/Optum-owned prescription discount service offering free coupons at independent and big-chain pharmacies nationwide; backed by the largest U.S. PBM.
RxSaver
Free prescription discount platform (acquired by Vericast/RetailMeNot lineage) that searches pharmacy prices and issues coupons; positioned as a no-membership alternative to GoodRx.
ScriptSave WellRx
Free prescription discount card available across the U.S., Guam, and Puerto Rico with a network of 65,000+ pharmacies; long-standing GoodRx alternative.
Blink Health
Digital pharmacy and prescription savings platform offering pre-paid medication pricing and home delivery; competes on transparent cash pricing for generics.
Amazon Pharmacy / RxPass
Amazon's pharmacy and prescription subscription service offering low-cost generics with Prime delivery; major retail-scale competitor pressuring GoodRx's pricing moat.
Yes, GoodRx is publicly traded under the ticker symbol GDRX on the NASDAQ. The company went public in September 23, 2020.
GoodRx trades under the ticker symbol GDRX on the NASDAQ. It began trading in September 23, 2020.
GoodRx (GDRX on the NASDAQ) shares can be purchased through any standard brokerage account — including Fidelity, Charles Schwab, TD Ameritrade, and online platforms like Robinhood or E*TRADE. Search for the ticker GDRX to place an order.
GoodRx went public in September 23, 2020 via ipo, with an offering valuation of approximately $2.8B. GoodRx completed its IPO on September 23, 2020, listing on the NASDAQ Global Select Market under the ticker GDRX. The offering priced at $33.00 per share, above the marketed range of $24-$28, raising approximately $1.14 billion on 34,615,384 shares sold and giving the company an initial market capitalization of roughly $12.7 billion. Shares closed the first trading day at $50.50, lifting market cap to about $19.4 billion. The company remains publicly traded as a healthcare/digital health stock; as of May 2026 market capitalization is approximately $864M with trailing-twelve-month revenue of about $797M.
GoodRx raised $1.14B across 4 disclosed funding rounds prior to its public listing.
GoodRx was co-founded by Trevor Bezdek, and Doug Hirsch in 2011.
GoodRx is headquartered in Santa Monica, CA, USA.
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.